Organon & Co. (OGN)
- Previous Close
18.42 - Open
18.43 - Bid 18.25 x 900
- Ask 18.75 x 2200
- Day's Range
18.33 - 18.68 - 52 Week Range
10.84 - 24.79 - Volume
1,989,811 - Avg. Volume
2,331,669 - Market Cap (intraday)
4.742B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
4.65 - EPS (TTM)
3.99 - Earnings Date May 2, 2024
- Forward Dividend & Yield 1.12 (6.04%)
- Ex-Dividend Date Feb 23, 2024
- 1y Target Est
21.50
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
www.organon.com10,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: OGN
Performance Overview: OGN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OGN
Valuation Measures
Market Cap
4.74B
Enterprise Value
12.81B
Trailing P/E
4.65
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.76
Price/Book (mrq)
--
Enterprise Value/Revenue
2.05
Enterprise Value/EBITDA
8.92
Financial Highlights
Profitability and Income Statement
Profit Margin
16.33%
Return on Assets (ttm)
7.22%
Return on Equity (ttm)
--
Revenue (ttm)
6.26B
Net Income Avi to Common (ttm)
1.02B
Diluted EPS (ttm)
3.99
Balance Sheet and Cash Flow
Total Cash (mrq)
693M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
395.25M
Research Analysis: OGN
Company Insights: OGN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: OGN
OGN: Raising target price to $17.00
ORGANON & CO has an Investment Rating of SELL; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetOGN: Lowering target price to $14.00
ORGANON & CO has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetOGN: Raising target price to $17.00
ORGANON & CO has an Investment Rating of SELL; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetOGN: What does Argus have to say about OGN?
ORGANON & CO has an Investment Rating of SELL; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target